Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 3, 2007, Pages 399-406

  Katori, Hideaki ^a,b   Tsukuda, Mamoru ^c   Watai, Kiichi ^c  

^a YOKOHAMA CITY MINATO RED CROSS HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Cisplatin; Docetaxel; Hyperfractionation radiotherapy; Squamous cell carcinoma of the head and neck (SCCHN)

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; RAMOSETRON;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE DISEASE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY; SURVIVAL ANALYSIS;

EID: 34250638712     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0370-y     Document Type: Article

References (30)

1. Million RR, Cassisi NJ (1994) Management of head and neck cancer. In: Cripps C (eds) A multidisciplinary approach. JB Lippincott, Philadelphia, pp 124-128
2. Horiot J, Le Fur R, N'Guyen T (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trail of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231-241
3. Horiot JC, Bontempts P, Begg AG (1998) New radiotherapy fractionation schemes in head and neck cancers. The EORTC trials: a benchmark. In: Kogelnik HD, Sedlymayer E (eds) Proceedings of the 6th international meeting on progress in radio-oncology VI, Monduzzi Editore, Bologna, pp 735-741
4. Al-Sarraf M, Pajak TF, Marcial VA (1987) Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck: an RTOG study. Cancer 59:259-265
5. Tobias JS, Smith BJ, Blackman G (1987) Concurrent daily cisplatin and radiotherapy in locally advanced squamous carcinoma of the head and neck and bronchus. Radiother Oncol 9:263-268
6. Browman GP, Cripps C, Hodson DI (1994) Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12:2648-2653
7. Withers HR (1985) Biologic basis for altered fractionated schemes. Cancer 55:2086-2095
8. Withers HR (1988) Inherent acceleration of tumor dose-rate in hyperfractionated regimens (letter). Int J Radiat Oncol Biol Phys 14:400
9. Withers HR, Peters LJ (1980) Biological aspects of radiation therapy. In: Fletcher GH (eds): Textbook of radiotherapy, 3rd edn. Lea and Febiger, Philadelphia, p 103-115
10. Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685-1689
11. Calais G, Alfonsi M, Bardet E (1999) Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086
12. Taylor S 4th, Murthy A, Vannetzel J (1994) Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 12:385-395
13. Janinis J, Papadakou G, Panagos G (1997) A phase II study of combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck and nasopharyngeal cancer. Proc Am Soc Clin Oncol 16:402a
14. Colevas A, Norris C, Tishler R (1999) Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 17:3503-3511
15. Schrijvers D, Van Herpen C, Kerger J (1999) Phase I-II study with Docetaxel (D), Cisplatin(C) and 5-Fluorouracil (5-FU) in patients (pts) with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN). Eur J Cancer 35(suppl 4):164a
16. Koukourakis M, Bizakis J, Skoulakis C (1999) Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res 19:2305-2309
17. Katori H, Tsukuda M, Mochimatu I (2004) Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 90:348-352
18. Katori H, Tsukuda M, Ishitoya J (2004) Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) (Abstr5560). Proc Am Soc Clin Oncol 22:14S
19. Katori H, Tsukuda M (2005) Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Clin Oncol 17:148-152
20. World Health Organization (1979) Handbook for reporting results of cancer treatment. In: World Health Organization (eds) WHO offset publication No. 48. World Health Organization, Geneva, pp 189-196
21. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
22. Inuyama Y, Kida A, Tsukuda M (2001) Late phase II study of S-1 in patients with advanced head and neck cancer. Jpn J Cancer Chemother 28:1381-1390
23. Thames HD, Withers HR, Peters LJ (1992) Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 8:219-226
24. Fu KK, Pajak TF, Trotti A (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16
25. Jeremic B, Shibamoto Y, Milicic B (2000) Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18:1458-64
26. Brizel DM, Albers ME, Fisher SR (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-804
27. Forastiere A, Neuberg D, Taylor S (1993) Phase II evaluation of taxol in advanced head and neck cancer: An Eastern Cooperative Oncology Group trial. Monogor Natl Cancer Inst 15:181-184
28. Catimel G, Verwij J, Hanauska A (1994) Docetaxel (taxotere): an active drug for treatment of the treatment of the head and neck. Ann Oncol 5:553-557
29. Dreyfuss A, Clark J, Norris C (1996) Docetaxel: an active drug for squamous cell carcinoma of head and neck. J Clin Oncol. 14:1672-1678
30. Mauer A, Masters G, Haraf D (1998) Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16:159-164